制癌剤1-(2-Tetrahydrofuryl)-5-fluorouracil(FT一207), の生体内運命(第3報)直腸内投与による吸収, 体内分布, 排泄および代謝

書誌事項

タイトル別名
  • Studies on the Fate of 1-(2-Tetrahydrofuryl)-5-fluorouracil (FT-207), a Carcinostatic Agent. III. Absorption, Distribution, Excretion and Metabolism after Rectal Administration of FT-207
  • 制癌剤1-(2-Tetrahydrofuryl)-5-fluorouracil(FT-207),の生体内運命-3-直腸内投与による吸収,体内分布,排泄および代謝
  • セイガンザイ 1 2 Tetrahydrofuryl 5 fluorourac

この論文をさがす

抄録

In order to investigate the fate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) in comparison with that of 5-fluorouracil tritiated FT-207 (3H-FT-207) and 5-fluovouracil (3H-5-fluorouracil)were administered from the rectum in normal and AH-130 tumor-bearing rats, and rapid absorption of 3H-FT-207 or 3H-5-fluorouracil, was observed. Blood level of radioactivity after rectal administration of 3H-FT-207 was higher and more continuous than that of 3H-5-fluorouracil. Although the radioactivity after rectal administration of 3H-FT-207 and 3H-5-fluovouracil was widely distributed in the various tissues of the animal with or without tumor, the highest concentration of the radioactivity was observed in the kidneys, and higher in tumor. The radioactivity in lymphatic gland reached a maximum level within 2-4 hr after the rectal administration of 3H-FT-207 and declined very slowly. The urinary excretion of radioactivity within 24 hr was about 30% of the administered dose of 3H-FT-207. More than 85% of the excreted radioactivity accounted for FT-207 and its metabolite, α-fluoro-β-alanine. Other metabolites such as 5-fluorouracil, α-fluoro-β-ureidopropionic acid and tritiated water were detected in small amounts in rat urine. The radioactivity in blood and tumor, 4 hr after rectal administration of 3H-FT-207, was found to represent FT-207. However, the radioactivity in liver was due to the presence of α-fluoro-β-alanine. About 90% radioactivity in lymphatic gland within 2-6 hr after rectal administration of 3H-FT-207 was detected as FT-207.

収録刊行物

  • 薬学雑誌

    薬学雑誌 95 (6), 732-740, 1975

    公益社団法人 日本薬学会

詳細情報 詳細情報について

問題の指摘

ページトップへ